Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food

scientific article published on March 2016

Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1086/685020
P932PMC publication ID4860539
P698PubMed publication ID27162630

P2093author name stringGeorg Wensing
Reiner Frey
Sigrun Unger
Wolfgang Mück
Corina Becker
Soundos Saleh
P2860cites workNO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialQ24656131
Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparationsQ30449094
Riociguat for the treatment of chronic thromboembolic pulmonary hypertensionQ33163081
Riociguat for the treatment of pulmonary arterial hypertensionQ33163083
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).Q34666291
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).Q34667642
NO-independent, haem-dependent soluble guanylate cyclase stimulatorsQ34906036
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertensionQ34917310
Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the InQ34999923
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary diseaseQ35010064
Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionalityQ36734217
Mechanisms of disease: pulmonary arterial hypertension.Q37892336
Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteersQ46562534
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat.Q50354785
Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension.Q51331643
Pulmonary Arterial HypertensionQ56388760
P433issueSuppl 1
P921main subjectriociguatQ2154494
pharmacokineticsQ323936
bioavailabilityQ461809
P304page(s)S66-74
P577publication date2016-03-01
P1433published inPulmonary circulationQ26842412
P1476titleBioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food
P478volume6

Reverse relations

cites work (P2860)
Q47584698Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
Q42696420Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects
Q90270317Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects
Q92785757Practical management of riociguat in patients with pulmonary arterial hypertension

Search more.